Blog

Product update: what's new in the OptInsight Consent & Preference platform We're pleased to share the latest developments at OptInsight. Over the past period, our Consent & Preference solution has…

Brand impact of not processing HCP data according to consent Failing to process HCP data according to consent damages a pharma brand in four ways: trust, access, reputation, and commercial…

Omnichannel engagement: Will you scale risk or impact? In our opinion, before #pharma can scale omnichannel, there’s one thing most teams forget: The basics. These 7 questions show exactly where…

You only get one chance as pharma with a specialist. In pharma and biotech, collecting consent from healthcare professionals (HCPs) is often treated as a compliance checkbox. But when biotech…

Why pharma and biotech companies need to move away from manual interfaces quickly and how it effects your business goals. I still see it a lot. Various systems are used…